UNC researcher develops innovative drug to treat Sickle Cell patients
Posted Dec 9, 2016
A new drug shows dramatic promise to help Sickle Cell patients reduce painful episodes. UNC's Dr. Kenneth Ataga was the principal investigator for an investigational drug called Crizanlizumab. The trial involved 198 participants in a multi-center, randomized trial. The “Sustain Trial” results were published online by the New England Journal of Medicine.
(WRAL.com)
Related: Campus Connections
UNC Alumna at Nike endows Carolina Covenant scholarshipIlana Finley ’00 is creating her own Tar Heel legacy by endowing a scholarship through the Carolina Covenant. After graduating with a bachelor’s degree in...
Fri Apr 19, 2024Chapel Hill restaurants foster relationships with UNC athletes
Behind name, image, and likeness deals that have encouraged high-profile athletes to consider business sponsorships, smaller restaurants in Chapel Hill have taken a different approach...
Wed Apr 17, 2024
ESPN announces 30 for 30 documentary on UNC alum Stuart Scott
ESPN Films will produce a 30 for 30 documentary on the extraordinary life of UNC alum Stuart Scott, who had many fans of the unique...
Mon Apr 15, 2024
‘You don’t see it every day’: Crowds gather at Morehead Planetarium to watch eclipse in Chapel Hill
Crowds of people spent the day at Morehead Planetarium and Science Center in Chapel Hill to take in the solar eclipse. By midafternoon, the moon...
Mon Apr 15, 2024